Anne Rancourt Named Director of Health Communication at FDA CTP

News by 2FIRSTS.ai

Apr.10.2024

Anne Rancourt Named Director of Health Communication at FDA CTP

Anne Rancourt named next director of CTP's Health Communication and Education Office by FDA, effective May 19.

The U.S. Food and Drug Administration (FDA) subsidiary Tobacco Products Center (CTP) recently announced that Anne Rancourt has been selected as the next director of the Office of Health Communication and Education. Rancourt previously served as the Communications Director at the National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH).

Lungkul has over 20 years of experience in strategic communications, behavior change projects, and news fields, including nearly 14 years of work in the federal government. She managed the communication department at NIDA, overseeing the dissemination of research findings on substance use and addiction worth nearly $2 billion, including tobacco and e-cigarette use. Prior to this, she also served as the Chief of Communications Science at the National Institute of Allergy and Infectious Diseases (NIAID).

CTP stated that Lankhul has been selected after undergoing a thorough nationwide search and passing the important ethical and safety review process by the FDA. She will take office on May 19th.

Also Read:

[1] Turning Point Brands Appoints Andrew Flynn as Chief Financial Officer

[2] PMI Appoints Christos Harpantidis as Senior Vice President

[3] KT&G CEO Appointment Uncertainty: Largest Shareholder Opposing

[4] Aziz Aliev Appointed as New General Manager of BAT Austria

#North America #United States #Traditional tobacco #FDA #Major companies

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

South Korea Implements Law Requiring Full Disclosure of Tobacco Harmful Substances

South Korea has enacted the Tobacco Harm Management Act, effective November 1, 2025, requiring tobacco manufacturers and importers to test and report harmful substances in their products every two years. Results for all tobacco types—including combustible cigarettes, heated tobacco, and e-cigarettes—will be publicly available from mid-2026.

Nov.04 by 2FIRSTS.ai

ARAC to 2Firsts | FDA’s Nicotine Pouch Pilot: What Hasn’t Changed Matters Most

In a contribution to 2Firsts, U.S. regulatory consultancy ARAC analyzes the FDA’s nicotine pouch PMTA pilot, cautioning that core evidentiary standards remain unchanged. The firm warns against overinterpreting the pilot and urges companies to act now rather than wait for uncertain regulatory shifts.

Oct.21

Product | Magnetic-attach design + mini display: FASTA’s new product goes on sale in the U.S., priced around $16

FASTA’s 40K Kit hits U.S. retailers: magnetic prefilled pods + reusable battery, mini display, two power levels; rated 20 mL/40,000 puffs/50 mg; some listings at $15.99.

Oct.15 by 2FIRSTS.ai

SKE’s Parent Company Yinghe Technology Reports 80% Drop in Q3 Net Profit, Revenue Up 22.85% Year-on-Year

Yinghe Technology (SZ: 300457), parent company of SKE, saw Q3 net profit plunge 80.3% to 31.06 million yuan, while revenue rose 22.85% to 2.52 billion yuan. The decline was mainly driven by higher costs and expenses.